About Lasa Supergenerics Limited
Data last updated: 14 July 2026
Lasa Supergenerics Limited is a public limited company based in Khed, Maharashtra, India, a subsidiary of Omkar Speciality Chemicals Limited. It specialises in animal pharmaceuticals and healthcare, a part of the broader pharmaceuticals sector. Incorporated on 11 March 2016, the company has been in operation for over 10 years.
Registered with ROC Mumbai under CIN L24233MH2016PLC274202. Listed on BSE: 540702 and NSE: LASA.
Capital: an authorised share capital of ₹100.33 Cr and a paid-up capital of ₹5.01 Cr. It is led by directors including Omkar Pravin Herlekar and Ketan Bhau Songal.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Khed, Maharashtra.
As per NSE-filed standalone financials for FY 2026, the company reported a revenue of ₹25.14 Cr, a decline of 82.35% compared to the previous year. The net worth stands at ₹49.62 Cr (down 40.72% YoY). Total assets are valued at ₹66.27 Cr (down 34.73% YoY).
The company has a workforce of approximately 326 employees as per the latest available data. It operates as a subsidiary of Omkar Speciality Chemicals Limited.
As per MCA filings, the company has satisfied charges of ₹84.64 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lasalabs.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressPlot No. C – 4 C – 4/1 Midc Lote Parshuram Industrial Area Tal – Khe, D, Khed, Maharashtra, India – 415722
-
IndustryPharma, Animal Pharmaceuticals & Healthcare
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Lasa Supergenerics Limited
Lasa Supergenerics Limited has one previous CIN (Corporate Identification Number): U24233MH2016PLC274202. The current CIN is L24233MH2016PLC274202, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233MH2016PLC274202 | Current |
| U24233MH2016PLC274202 | Previous |
Business Activity of Lasa Supergenerics Limited
Lasa Supergenerics Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Lasa Supergenerics Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Lasa Supergenerics Limited
Lasa Supergenerics Limited is audited by Gupta Rustagi & Co (ICAI peer reviewed, certificate valid till 2028-02-29) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Gupta Rustagi & Co (ICAI peer reviewed, certificate valid till 2028-02-29) | FY 2026 | Statement on impact of audit qualification |
Board of Directors of Lasa Supergenerics Limited
Lasa Supergenerics Limited is currently managed by 6 directors, with 15 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Omkar Pravin Herlekar | Managing Director | 11 Mar 2016 | 10 Years 5 Months | Current |
|
Ketan Bhau Songal
Also directs:
Lasa Supergenerics Limited
|
Director | 04 Aug 2025 | 1 Years 0 Months | Current |
|
Pravin Gadalya Lachake
Also directs:
Lasa Supergenerics Limited
|
Director | 04 Aug 2025 | 1 Years 0 Months | Current |
|
Yogesh Hari Ughada
Also directs:
Lasa Supergenerics Limited
|
Director | 04 Aug 2025 | 1 Years 0 Months | Current |
|
Rekha Hemant Wakh
Also directs:
Lasa Supergenerics Limited
|
Director | 04 Aug 2025 | 1 Years 0 Months | Current |
|
Ganesh Suresh Potdar
Also directs:
Lasa Supergenerics Limited
|
Additional Director | 02 Jan 2026 | 0 Years 7 Months | Current |
Financials of Lasa Supergenerics Limited FY 2026 filings available
Lasa Supergenerics Limited reported revenue of ₹25.14 Cr (down 82.35% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹25.14 Cr | ₹142.45 Cr | ₹104.34 Cr | ₹129.57 Cr | ₹137.13 Cr | ₹202.38 Cr | ₹167.27 Cr |
| Other Income | ₹19.98 Lakh | ₹5.01 Cr | ₹9.93 Lakh | ₹1.8 Cr | ₹5.74 Lakh | ₹5.76 Lakh | ₹23.16 Lakh |
| Total Income | ₹25.34 Cr | ₹147.46 Cr | ₹104.43 Cr | ₹131.37 Cr | ₹137.18 Cr | ₹202.44 Cr | ₹167.5 Cr |
| Cost of Materials Consumed | ₹19.15 Cr | ₹108.1 Cr | ₹79.28 Cr | ₹110.12 Cr | ₹88.21 Cr | ₹102.11 Cr | ₹86.51 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹6.25 Cr | ₹0 | ₹49.41 Lakh |
| Changes in Inventories | ₹4.69 Cr | -₹1.91 Cr | -₹4.06 Cr | -₹4.01 Cr | -₹3.17 Cr | ₹10.24 Cr | ₹7.65 Cr |
| Employee Benefit Expense | ₹2.17 Cr | ₹6.11 Cr | ₹6.34 Cr | ₹7.37 Cr | ₹9.93 Cr | ₹14.01 Cr | ₹13.42 Cr |
| Finance Costs | ₹38.62 Lakh | ₹2.69 Cr | ₹1.93 Cr | ₹4.16 Cr | ₹4.03 Lakh | ₹1.96 Cr | ₹8.1 Cr |
| Depreciation & Amortisation | ₹6.02 Cr | ₹12.3 Cr | ₹10.67 Cr | ₹13.42 Cr | ₹14 Cr | ₹15.82 Cr | ₹17.34 Cr |
| Other Expenses | ₹27.53 Cr | ₹23.89 Cr | ₹20.61 Cr | ₹22.68 Cr | ₹20.27 Cr | ₹28.8 Cr | ₹29.25 Cr |
| Total Expenses | ₹59.95 Cr | ₹151.17 Cr | ₹114.77 Cr | ₹153.74 Cr | ₹135.53 Cr | ₹172.95 Cr | ₹162.77 Cr |
| Profit Before Exceptional Items & Tax | -₹34.61 Cr | -₹3.71 Cr | -₹10.34 Cr | -₹22.37 Cr | ₹1.65 Cr | ₹29.49 Cr | ₹4.74 Cr |
| Exceptional Items | ₹0 | -₹15.67 Cr | -₹8.77 Cr | -₹19.9 Cr | -₹7.86 Cr | ₹0 | ₹0 |
| Profit Before Tax | -₹34.61 Cr | -₹19.38 Cr | -₹19.11 Cr | -₹42.27 Cr | -₹6.21 Cr | ₹29.49 Cr | ₹4.74 Cr |
| Total Tax Expense | -₹51.74 Lakh | -₹4.63 Cr | ₹2.62 Cr | -₹3.69 Cr | -₹1.46 Cr | ₹7.62 Cr | ₹74.02 Lakh |
| Net Profit | -₹34.09 Cr | -₹14.76 Cr | -₹21.73 Cr | -₹38.62 Cr | -₹5.37 Cr | ₹22.78 Cr | ₹3.63 Cr |
| Other Comprehensive Income | ₹0 | ₹4.42 Lakh | ₹11.54 Lakh | ₹3.91 Lakh | ₹6.1 Lakh | ₹0 | ₹3.95 Lakh |
| Total Comprehensive Income | -₹34.09 Cr | -₹14.71 Cr | -₹21.62 Cr | -₹38.58 Cr | -₹5.31 Cr | ₹22.78 Cr | ₹3.67 Cr |
| EBITDA (computed) | -₹28.2 Cr | ₹11.28 Cr | ₹2.27 Cr | -₹4.79 Cr | ₹15.69 Cr | ₹47.28 Cr | ₹30.18 Cr |
| Basic EPS | ₹-6.80 | ₹-2.95 | ₹-4.34 | ₹-7.71 | ₹-1.32 | ₹5.60 | ₹1.26 |
| Diluted EPS | ₹-6.80 | ₹-2.95 | ₹-4.34 | ₹-7.71 | ₹-1.32 | ₹5.60 | ₹1.26 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹66.27 Cr | ₹101.53 Cr | ₹150.87 Cr | ₹163.85 Cr |
| Non-current Assets | ₹55.83 Cr | ₹69.02 Cr | ₹112.98 Cr | ₹124.63 Cr |
| Current Assets | ₹10.44 Cr | ₹32.51 Cr | ₹37.89 Cr | ₹39.22 Cr |
| Property, Plant & Equipment | ₹38.38 Cr | ₹48.09 Cr | ₹83.82 Cr | ₹88.13 Cr |
| Inventories | ₹1.82 Cr | ₹24.5 Cr | ₹19.04 Cr | ₹13.9 Cr |
| Trade Receivables | ₹4.12 Lakh | ₹1.49 Cr | ₹3.59 Cr | ₹2.48 Cr |
| Cash & Equivalents | ₹28.78 Lakh | ₹27.53 Lakh | ₹60.86 Lakh | ₹79.95 Lakh |
| Equity (Net Worth) | ₹49.62 Cr | ₹83.71 Cr | ₹96.68 Cr | ₹118.29 Cr |
| Equity Share Capital | ₹50.1 Cr | ₹50.1 Cr | ₹50.1 Cr | ₹50.1 Cr |
| Borrowings (Non-current) | ₹0 | ₹44.22 Lakh | ₹0 | ₹0 |
| Borrowings (Current) | ₹9.75 Cr | ₹2.13 Cr | ₹22.08 Cr | ₹0 |
| Total Debt (computed) | ₹9.75 Cr | ₹2.57 Cr | ₹22.08 Cr | ₹0 |
| Current Liabilities | ₹16.77 Cr | ₹17.15 Cr | ₹48.87 Cr | ₹42.73 Cr |
| Total Liabilities | ₹16.65 Cr | ₹17.82 Cr | ₹54.19 Cr | ₹45.57 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹22.83 Cr | -₹2.82 Cr | ₹2.14 Cr | -₹33.51 Cr | ₹10.49 Cr |
| Investing Cash Flow | ₹0 | ₹8.15 Cr | -₹39.78 Lakh | ₹1.53 Cr | -₹3.25 Cr |
| Financing Cash Flow | ₹0 | -₹5.66 Cr | -₹1.93 Cr | ₹4.16 Cr | -₹4.03 Lakh |
| Capital Expenditure | ₹0 | ₹0 | -₹66.08 Lakh | ₹4.83 Cr | -₹2.28 Cr |
| Free Cash Flow (computed) | -₹22.83 Cr | -₹2.82 Cr | ₹1.48 Cr | -₹38.34 Cr | ₹8.21 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹22.83 Cr | -₹33.33 Lakh | -₹19.14 Lakh | -₹27.02 Cr | ₹7.2 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | -₹13.15 Lakh | ₹2.2 Cr | ₹3.06 Cr | ₹20.01 Cr | ₹39.14 Cr | ₹33.08 Cr | ₹39.39 Cr | ₹30.84 Cr | ₹22.82 Cr | ₹26.66 Cr | ₹24.3 Cr | ₹30.56 Cr |
| Other Income | ₹4.07 Lakh | ₹1.79 Lakh | ₹70,000 | ₹13.42 Lakh | ₹2.39 Cr | ₹14.21 Lakh | ₹1.95 Cr | ₹47,000 | ₹79,000 | ₹36,000 | ₹8.4 Lakh | ₹39,000 |
| Total Income | -₹9.08 Lakh | ₹2.22 Cr | ₹3.07 Cr | ₹20.15 Cr | ₹41.53 Cr | ₹33.22 Cr | ₹41.34 Cr | ₹30.84 Cr | ₹22.82 Cr | ₹26.66 Cr | ₹24.39 Cr | ₹30.56 Cr |
| Cost of Materials Consumed | ₹66.83 Lakh | ₹48.77 Lakh | ₹4.33 Cr | ₹13.66 Cr | ₹31.68 Cr | ₹25.83 Cr | ₹30.28 Cr | ₹20.3 Cr | ₹19.04 Cr | ₹18.39 Cr | ₹19.65 Cr | ₹22.2 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹30.48 Lakh | ₹1.77 Cr | ₹1.2 Cr | ₹2.03 Cr | -₹3.36 Cr | -₹1.32 Cr | ₹1 Cr | ₹1.76 Cr | -₹56.06 Lakh | ₹1.54 Cr | -₹3.14 Cr | -₹1.9 Cr |
| Employee Benefit Expense | ₹4.65 Lakh | ₹16.35 Lakh | ₹78.27 Lakh | ₹1.18 Cr | ₹1.43 Cr | ₹1.47 Cr | ₹1.59 Cr | ₹1.62 Cr | ₹1.51 Cr | ₹1.55 Cr | ₹1.59 Cr | ₹1.69 Cr |
| Finance Costs | ₹12.86 Lakh | ₹11.2 Lakh | ₹11.95 Lakh | ₹2.6 Lakh | ₹10.77 Lakh | ₹47.21 Lakh | ₹1.24 Cr | ₹87.15 Lakh | ₹56.02 Lakh | ₹44.1 Lakh | ₹55.76 Lakh | ₹37.32 Lakh |
| Depreciation & Amortisation | ₹1.31 Cr | ₹1.57 Cr | ₹1.57 Cr | ₹1.57 Cr | ₹3.9 Cr | ₹2.8 Cr | ₹2.81 Cr | ₹2.79 Cr | ₹2.66 Cr | ₹2.68 Cr | ₹2.68 Cr | ₹2.65 Cr |
| Other Expenses | ₹2.04 Cr | ₹52.4 Lakh | ₹74.47 Lakh | ₹3.65 Cr | ₹5.97 Cr | ₹6.3 Cr | ₹5.73 Cr | ₹5.35 Cr | ₹6.81 Cr | ₹4.13 Cr | ₹5.16 Cr | ₹4.51 Cr |
| Total Expenses | ₹3.89 Cr | ₹4.63 Cr | ₹8.75 Cr | ₹22.11 Cr | ₹39.73 Cr | ₹35.56 Cr | ₹42.66 Cr | ₹32.7 Cr | ₹30.02 Cr | ₹28.73 Cr | ₹26.5 Cr | ₹29.53 Cr |
| Profit Before Exceptional Items & Tax | -₹3.98 Cr | -₹2.41 Cr | -₹5.68 Cr | -₹1.96 Cr | ₹1.8 Cr | -₹2.34 Cr | -₹1.31 Cr | -₹1.86 Cr | -₹7.19 Cr | -₹2.06 Cr | -₹2.11 Cr | ₹1.03 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | -₹20.57 Cr | -₹23.91 Cr | ₹8.25 Cr | ₹0 | ₹0 | -₹8.77 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹3.98 Cr | -₹2.41 Cr | -₹5.68 Cr | -₹22.54 Cr | -₹22.12 Cr | ₹5.91 Cr | -₹1.31 Cr | -₹1.86 Cr | -₹15.97 Cr | -₹2.06 Cr | -₹2.11 Cr | ₹1.03 Cr |
| Total Tax Expense | ₹18.76 Lakh | ₹14.31 Lakh | ₹57.12 Lakh | -₹1.42 Cr | -₹7.83 Cr | ₹41.58 Lakh | ₹1.92 Cr | ₹86.85 Lakh | -₹66.74 Lakh | -₹60.59 Lakh | -₹2.09 Cr | ₹5.98 Cr |
| Net Profit | -₹4.16 Cr | -₹2.55 Cr | -₹6.25 Cr | -₹21.12 Cr | -₹14.29 Cr | ₹5.49 Cr | -₹3.23 Cr | -₹2.73 Cr | -₹15.3 Cr | -₹1.46 Cr | -₹2.29 Lakh | -₹4.95 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹4.42 Lakh | ₹0 | ₹0 | ₹0 | ₹11.54 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹4.16 Cr | -₹2.55 Cr | -₹6.25 Cr | -₹21.12 Cr | -₹14.25 Cr | ₹5.49 Cr | -₹3.23 Cr | -₹2.73 Cr | -₹15.18 Cr | -₹1.46 Cr | -₹2.29 Lakh | -₹4.95 Cr |
| EBITDA (computed) | -₹2.54 Cr | -₹72.97 Lakh | -₹3.99 Cr | -₹36.82 Lakh | ₹5.8 Cr | ₹93.24 Lakh | ₹2.74 Cr | ₹1.8 Cr | -₹3.97 Cr | ₹1.06 Cr | ₹1.13 Cr | ₹4.05 Cr |
| Basic EPS | ₹-0.83 | ₹-0.51 | ₹-1.25 | ₹-4.22 | ₹-2.85 | ₹1.10 | ₹0.64 | ₹0.55 | ₹-3.05 | ₹-0.29 | ₹0.00 | ₹-0.99 |
| Diluted EPS | ₹-0.83 | ₹-0.51 | ₹-1.25 | ₹-4.22 | ₹-2.85 | ₹1.10 | ₹0.64 | ₹0.55 | ₹-3.05 | ₹-0.29 | ₹0.00 | ₹-0.99 |
Shareholding Pattern of Lasa Supergenerics Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 53.65%, retail and other public shareholders hold 46.35% of Lasa Supergenerics Limited. The company had 27,702 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% |
| Public | 46.35% | 46.35% | 46.35% | 46.35% | 46.35% | 46.35% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.65% | 53.65% | 53.65% | 53.65% | 43.78% | 64.47% | 64.47% | 34.59% | 38.16% |
| Public | 46.35% | 46.35% | 46.35% | 46.35% | 56.22% | 35.53% | 35.53% | 65.41% | 61.84% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | +0.00 | +9.87 | -20.69 | +0.00 | +29.88 | -3.57 | - |
Board & Governance of Lasa Supergenerics Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Lasa Supergenerics Limited has 6 directors - 4 independent and 2 executive. The board is chaired by Omkar Pravin Herlekar.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Omkar Pravin Herlekar | Executive Director · MD · Chairperson | 2016-03-11 | 1 |
| Ganesh Suresh Potdar | Executive Director · MD | 2026-01-02 | 1 |
| Ketan Bhau Songal | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Pravin Gadalya Lachake | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Yogesh Hari Ughada | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Rekha Hemant Wakh | Non-Executive - Independent Director | 2025-08-04 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Ketan Bhau Songal (Chairperson), Rekha Hemant Wakh, Omkar Pravin Herlekar |
| Nomination and remuneration committee | Ketan Bhau Songal (Chairperson), Rekha Hemant Wakh, Pravin Gadalya Lachake |
| Stakeholders Relationship Committee | Pravin Gadalya Lachake (Chairperson), Yogesh Hari Ughada, Omkar Pravin Herlekar |
| Corporate Social Responsibility Committee | Pravin Gadalya Lachake (Chairperson), Omkar Pravin Herlekar, Yogesh Hari Ughada |
| Enquiry Committee | Omkar Pravin Herlekar (Chairperson), Ketan Bhau Songal, Pravin Gadalya Lachake |
| Advisory Committee | Omkar Pravin Herlekar (Chairperson), Ketan Bhau Songal, Rekha Hemant Wakh |
| Fund Raising Committee | Omkar Pravin Herlekar (Chairperson), Ketan Bhau Songal, Yogesh Hari Ughada, Pravin Gadalya Lachake |
Charges & Borrowings of Lasa Supergenerics Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Apr 2018 | Others | ₹6.03 Cr | Satisfied |
| 31 Mar 2018 | Others | ₹1.82 Cr | Satisfied |
| 28 Nov 2012 | Axis Bank Limited | ₹76.79 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Lasa Supergenerics Limited
Lasa Supergenerics Limited has a workforce of 326 employees as of Apr 07, 2024.
Employee and EPFO history for Lasa Supergenerics Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Lasa Supergenerics Limited
GST registrations and filing compliance for Lasa Supergenerics Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Lasa Supergenerics Limited
Credit ratings, litigation, and regulatory alerts for Lasa Supergenerics Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Lasa Supergenerics Limited
MSME payment history for Lasa Supergenerics Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Lasa Supergenerics Limited
Corporate group structure for Lasa Supergenerics Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Lasa Supergenerics Limited
MCA filings and documents for Lasa Supergenerics Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Lasa Supergenerics Limited
Recent News on Lasa Supergenerics Limited
Frequently Asked Questions about Lasa Supergenerics Limited
Lasa Supergenerics Limited is an active public limited company in the pharma sector based in Khed, Maharashtra, India. It was incorporated on 11 March 2016 (10+ years old) and is registered under CIN L24233MH2016PLC274202. Listed on BSE: 540702 and NSE: LASA. The company has 326 employees.
Lasa Supergenerics Limited reported revenue of ₹25.14 Cr for FY 2026 (down 82.35% YoY) based on standalone NSE filings.
The current directors of Lasa Supergenerics Limited are:
- Omkar Pravin Herlekar - Managing Director
- Ketan Bhau Songal - Director
- Pravin Gadalya Lachake - Director
- Yogesh Hari Ughada - Director
- Rekha Hemant Wakh - Director
- Ganesh Suresh Potdar - Additional Director
The primary industry of Lasa Supergenerics Limited is pharma. The company specifically operates in animal pharmaceuticals and healthcare. The company is currently active in this sector.
Yes. Lasa Supergenerics Limited is listed on both BSE (code: 540702) and NSE (symbol: LASA).
Lasa Supergenerics Limited can be reached at the registered office: Plot No. C – 4 C – 41 Midc Lote Parshuram Industrial Area Tal – Khe, D, Khed, Maharashtra, India – 415722, or through the website lasalabs.com.